Institut für Radiologie, Nuklearmedizin und Molekulare Bildgebung, Herz- und Diabeteszentrum NRW, Georgstr. 11, Bad Oeynhausen, Germany.
Klinische Abteilung für Nuklearmedizin, Universitätsklinik für Radiologie und Nuklearmedizin, Medizinische Universität Wien, Vienna, Austria.
Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3602-3608. doi: 10.1007/s00259-023-06336-8. Epub 2023 Jul 15.
This paper presents the results of the first joint survey on the use of SPECT and PET myocardial perfusion imaging (MPI) and cardiac amyloidosis imaging in Austria, Germany, and Switzerland of the year 2021.
A questionnaire was sent in 2022 to centres practicing nuclear medicine.
Data from 14 Austrian (10,710 SPECT), 218 German (133,047 SPECT), and 16 Swiss centres (11,601 MPI (6,879 SPECT, 4722 PET)) were analysed. In Austria and Germany, the PET MPI numbers were close to zero and not considered. Official MPS numbers from 2015 to 2021 from Austria and Germany revealed a decline in Austria by about 40% in the pandemic years 2020 to 2021, but an increase in Germany by 9%. Ambulatory care cardiologists represented the major referral group (56-71%). Mostly, stress tests were performed pharmacologically (58-92%). Contrary to Germany, a 1-day protocol was predominant (58-97%) in Austria and Switzerland. The leading camera systems were SPECT-CT in Austria and Switzerland (57-79%) and multi-head systems in Germany (58%). Switzerland had the highest proportion of SPECT MPI with attenuation correction (84%), followed by Austria (43%), and Germany (33%). Electrocardiogram-gated SPECT MPI showed an overall high penetration of 87-99%. Scoring was most frequently applied in Germany (72%), followed by Austria (64%), and Switzerland (60%). Related to the population, the number of cardiac amyloidosis imaging was highest in Austria, followed by Switzerland and Germany.
This first joint survey of 2021 shows considerable differences among the countries. The Swiss situation is outstanding due to the wide use of PET MPI. In terms of camera equipment, Switzerland is also leading, followed by Austria and Germany. Despite the differences in procedural issues, the results reveal an overall high standard of MPI imaging.
本文呈现了 2021 年奥地利、德国和瑞士首次联合调查 SPECT 和 PET 心肌灌注成像（MPI）以及心脏淀粉样变性成像使用情况的结果。
2022 年向核医学中心发放了调查问卷。
对来自 14 家奥地利（10710 例 SPECT）、218 家德国（133047 例 SPECT）和 16 家瑞士中心（11601 例 MPI（6879 例 SPECT，4722 例 PET））的数据进行了分析。在奥地利和德国，PET MPI 数量接近零，未予考虑。来自奥地利和德国的 2015 年至 2021 年的官方 MPS 数据显示，在 2020 年至 2021 年的大流行期间，奥地利的数量下降了约 40%，而德国则增长了 9%。流动心脏病学家是主要的转诊群体（56%-71%）。大多数情况下，采用药物负荷进行应激试验（58%-92%）。与德国不同，奥地利和瑞士主要采用 1 天方案（58%-97%）。主要的相机系统为奥地利和瑞士的 SPECT-CT（57%-79%）和德国的多头系统（58%）。瑞士的 SPECT MPI 中应用衰减校正的比例最高（84%），其次是奥地利（43%）和德国（33%）。心电图门控 SPECT MPI 的总体穿透率很高，为 87%-99%。评分在德国最为常用（72%），其次是奥地利（64%）和瑞士（60%）。与人口相比，奥地利的心脏淀粉样变性成像数量最高，其次是瑞士和德国。
这是 2021 年首次联合调查，各国之间存在显著差异。由于广泛使用 PET MPI，瑞士的情况尤为突出。在相机设备方面，瑞士也处于领先地位，其次是奥地利和德国。尽管在程序问题上存在差异，但结果显示 MPI 成像总体上具有很高的标准。
